The signal strength of Relugolix (Orgovyx<sup>®</sup>) at the System Organ Class (SOC) level.
<p>The signal strength of Relugolix (Orgovyx<sup>®</sup>) at the System Organ Class (SOC) level.</p>
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1852025780211548160 |
|---|---|
| author | Ruibo Li (2063167) |
| author2 | Xi Chen (35903) Yujie Wang (308942) |
| author2_role | author author |
| author_facet | Ruibo Li (2063167) Xi Chen (35903) Yujie Wang (308942) |
| author_role | author |
| dc.creator.none.fl_str_mv | Ruibo Li (2063167) Xi Chen (35903) Yujie Wang (308942) |
| dc.date.none.fl_str_mv | 2024-10-22T17:40:35Z |
| dc.identifier.none.fl_str_mv | 10.1371/journal.pone.0312481.t003 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/The_signal_strength_of_Relugolix_Orgovyx_sup_sup_at_the_System_Organ_Class_SOC_level_/27278835 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Medicine Cell Biology Pharmacology Biotechnology Immunology Cancer Biological Sciences not elsewhere classified ‘ primary suspected take timely prevention reporting odds ratios rare adverse events prostate cancer based may remain undetected avoid serious consequences 26 organ systems adverse events analysis first 30 days unexpected significant aes ps )’ aes aes occurred within market data analysis faers database covering ensure drug safety disproportionality analysis safety information faers database 60 days aes associated treatment measures third quarter side effects potential risks fourth quarter four algorithms comprehensively analyze clinical trials bcpnn ), 397 reports 189 reports |
| dc.title.none.fl_str_mv | The signal strength of Relugolix (Orgovyx<sup>®</sup>) at the System Organ Class (SOC) level. |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>The signal strength of Relugolix (Orgovyx<sup>®</sup>) at the System Organ Class (SOC) level.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_f65ea50f856896f2d97d18fdd5bcdb46 |
| identifier_str_mv | 10.1371/journal.pone.0312481.t003 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/27278835 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | The signal strength of Relugolix (Orgovyx<sup>®</sup>) at the System Organ Class (SOC) level.Ruibo Li (2063167)Xi Chen (35903)Yujie Wang (308942)MedicineCell BiologyPharmacologyBiotechnologyImmunologyCancerBiological Sciences not elsewhere classified‘ primary suspectedtake timely preventionreporting odds ratiosrare adverse eventsprostate cancer basedmay remain undetectedavoid serious consequences26 organ systemsadverse events analysisfirst 30 daysunexpected significant aesps )’ aesaes occurred withinmarket data analysisfaers database coveringensure drug safetydisproportionality analysissafety informationfaers database60 daysaes associatedtreatment measuresthird quarterside effectspotential risksfourth quarterfour algorithmscomprehensively analyzeclinical trialsbcpnn ),397 reports189 reports<p>The signal strength of Relugolix (Orgovyx<sup>®</sup>) at the System Organ Class (SOC) level.</p>2024-10-22T17:40:35ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.1371/journal.pone.0312481.t003https://figshare.com/articles/dataset/The_signal_strength_of_Relugolix_Orgovyx_sup_sup_at_the_System_Organ_Class_SOC_level_/27278835CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/272788352024-10-22T17:40:35Z |
| spellingShingle | The signal strength of Relugolix (Orgovyx<sup>®</sup>) at the System Organ Class (SOC) level. Ruibo Li (2063167) Medicine Cell Biology Pharmacology Biotechnology Immunology Cancer Biological Sciences not elsewhere classified ‘ primary suspected take timely prevention reporting odds ratios rare adverse events prostate cancer based may remain undetected avoid serious consequences 26 organ systems adverse events analysis first 30 days unexpected significant aes ps )’ aes aes occurred within market data analysis faers database covering ensure drug safety disproportionality analysis safety information faers database 60 days aes associated treatment measures third quarter side effects potential risks fourth quarter four algorithms comprehensively analyze clinical trials bcpnn ), 397 reports 189 reports |
| status_str | publishedVersion |
| title | The signal strength of Relugolix (Orgovyx<sup>®</sup>) at the System Organ Class (SOC) level. |
| title_full | The signal strength of Relugolix (Orgovyx<sup>®</sup>) at the System Organ Class (SOC) level. |
| title_fullStr | The signal strength of Relugolix (Orgovyx<sup>®</sup>) at the System Organ Class (SOC) level. |
| title_full_unstemmed | The signal strength of Relugolix (Orgovyx<sup>®</sup>) at the System Organ Class (SOC) level. |
| title_short | The signal strength of Relugolix (Orgovyx<sup>®</sup>) at the System Organ Class (SOC) level. |
| title_sort | The signal strength of Relugolix (Orgovyx<sup>®</sup>) at the System Organ Class (SOC) level. |
| topic | Medicine Cell Biology Pharmacology Biotechnology Immunology Cancer Biological Sciences not elsewhere classified ‘ primary suspected take timely prevention reporting odds ratios rare adverse events prostate cancer based may remain undetected avoid serious consequences 26 organ systems adverse events analysis first 30 days unexpected significant aes ps )’ aes aes occurred within market data analysis faers database covering ensure drug safety disproportionality analysis safety information faers database 60 days aes associated treatment measures third quarter side effects potential risks fourth quarter four algorithms comprehensively analyze clinical trials bcpnn ), 397 reports 189 reports |